Pathway link EVE-RCC

Everolimus ⊣ Renal cell carcinoma (RCC)

Everolimus inhibits Renal cell carcinoma (RCC).

In a clinical trial, everolimus roughly doubled the time before advanced kidney cancer got worse, after other treatments had stopped working.

RECORD-1: everolimus roughly doubled progression-free survival after other targeted therapy failed.

The conditions it holds under

Second-line setting, after VEGF-targeted therapy - not first-line.

Time it takes

long exposure (days to weeks)

Step

indirect (through steps not drawn here)

Measured in

human

Reaches people?

shown in people

How settled

settled in the literature

Studies behind it

Points the other way

No study in the Atlas contradicts this link. That means none in this curated set, not none in the literature.

Who has checked this

Checked by

No researcher outside the project has checked this link yet.

Curator sign-off

Not signed off yet. This link was drafted with AI help and has not been reviewed link by link; treat it as a proposal until it is.

Curated by

Oliver Barton, with AI help for drafting; see how links are checked.

“Inhibits” describes the effect on the target's activity, not on how much of it there is.

“How settled” describes how far researchers in the field agree. It is not the same as the sign-off above, which only says whether a named curator has checked this page.

If this link rests on your own work: a click on “This looks right” below, or a short note through “Report an error”, helps us more than anything else on this page.

← The whole pathway · This link as JSON